Given the increased frequency of CD8+PD-1+ T lymphocytes observed in co-cultures in the presence of itolizumab and the clinical benefits reported for combinatorial therapies of different ICIs (29), the effect of the combination of itolizumab with pembrolizumab on PBMCs-induced tumor cell killing in vitro was evaluated. The gene discussed is CD8A; the disease is neoplasm.